Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 134Lung Neoplasms 50Breast Neoplasms 24Head and Neck Neoplasms 22Adenocarcinoma of Lung 18Brain Neoplasms 15Neoplasms 14Adenocarcinoma, Bronchiolo-Alveolar 11Squamous Cell Carcinoma of Head and Neck 10Glioblastoma 9Esophageal Neoplasms 9Colorectal Neoplasms 9NSCLC 8Rectal Neoplasms 7Prostatic Neoplasms 7Neoplasm Metastasis 7Gliosarcoma 7Colonic Neoplasms 7Adenocarcinoma Of Esophagus 7Ovarian Neoplasms 5Esophageal Squamous Cell Carcinoma 5Adenocarcinoma 5Urinary Bladder Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Renal Cell 4Carcinoma 4Unspecified Adult Solid Tumor, Protocol Specific 3Skin Neoplasms 3Respiratory Tract Diseases 3Kidney Neoplasms 3

Interventions

Pemetrexed 8Carboplatin 6Cisplatin 4Bevacizumab 4pembrolizumab 3anlotinib 3Platinum 2Paclitaxel 2tusamitamab ravtansine 1ixabepilone 1icotinib 1endostar protein 1camrelizumab 1Gefitinib 1Erlotinib Hydrochloride 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-squamous Non-small Cell Lung Cancer × Gefitinib × Clear all
NCT03602027 2018-07-26

Phase I Study of the Combination of Anlotinib With Gefitinib

Second Affiliated Hospital of Nanchang University

Phase NA Unknown
9 enrolled
Thoracic

Non-squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡